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Abstract 
Antibodies are capable of potently and specifically binding individual antigens and, in some cases, disrupting their functions. 
The key challenge in generating antibody-based inhibitors is the lack of fundamental information relating sequences of 
antibodies to their unique properties as inhibitors. We develop a pipeline, Antibody Sequence Analysis Pipeline using Statistical 
testing and Machine Learning (ASAP-SML), to identify features that distinguish one set of antibody sequences from antibody 
sequences in a reference set. The pipeline extracts feature fingerprints from sequences. The fingerprints represent germline, 
CDR canonical structure, isoelectric point and frequent positional motifs. Machine learning and statistical significance testing 
techniques are applied to antibody sequences and extracted feature fingerprints to identify distinguishing feature values and 
combinations thereof. To demonstrate how it works, we applied the pipeline on sets of antibody sequences known to bind or 
inhibit the activities of matrix metalloproteinases (MMPs), a family of zinc-dependent enzymes that promote cancer 
progression and undesired inflammation under pathological conditions, against reference datasets that do not bind or inhibit 
MMPs. ASAP-SML identifies features and combinations of feature values found in the MMP-targeting sets that are distinct 
from those in the reference sets.  
Author summary 
The availability of machine learning techniques and the exponential growth of sequencing data presents new opportunities to 
identify features that endow antibodies with the ability to disrupt the functions of biological targets. We have created a pipeline 
 that uses statistical testing and machine learning techniques to determine features that are overrepresented in a specified set of 
antibody sequences in comparison to a reference set. The pipeline is referred to as Antibody Sequence Analysis Pipeline using 
Statistical testing and Machine Learning (ASAP-SML). We demonstrate the use of ASAP-SML by analyzing sets of antibodies 
that inhibit matrix metalloproteinases (MMPs) against reference sets. ASAP-SML performs within and across set similarity 
analysis. As in prior studies, our analysis of these datasets shows that features associated with the antibody heavy chain are 
more likely to differentiate MMP-targeting antibody sequences from reference antibody sequences. Further, ASAP-SML 
identifies several features in the MMP-targeting set that are distinct from the reference sets. Using design recommendation 
trees, ASAP-SML suggests combinations of features that can be included or excluded to augment the targeting set with 
additional candidate MMP-targeting antibody sequences.  
 
Introduction  
Antibodies play an important role in treating diseases such as cancer and autoimmunity disorders by blocking specific protein-
protein interactions and recruiting the immune system to specific cells and tissues. While experimental methods for antibody 
discovery, including hybridoma technology (1) and phage and yeast display (2), have allowed for significant advances in 
discovering specific binding proteins, difficulties remain in establishing general strategies for designing antibodies that disrupt 
enzymatic activity or other biological functions. In particular, relating the amino acid sequences of these antibodies to their 
unique abilities in disrupting biological functions remains a challenge. Data-driven computational approaches may shed light 
on such fundamental information. Recent computational tools provide first steps towards elucidating structural information 
that can guide rational antibody design. Several numbering tools (e.g., AbNum (3), DomainGapAlign (4), PyIgClassify (5), 
ANARCI (6), and AbYsis (7)) annotate an antibody sequence to identify the Complementary Determining Regions (CDRs) 
and the Framework Regions (FRs). There are also tools (e.g., IgBLAST (8) and SAbDab (9)) to select templates from databases 
for the variable domains VH and VL. Other tools (e.g., PIGS (10), FREAD (11), PyIGClassify) predict the structures of CDR 
loops. Efforts to partially design antibody sequences that bind to specific targets have been made utilizing several computational 
tools (e.g. OptMaven (12) and RAbD (13)). These tools graft designed CDRs on backbones, and then utilize energy 
minimization and optional docking procedures to obtain complete antibody sequences. Despite these and other efforts (14, 15), 
there remains a critical gap in linking antibody sequences directly to biological consequences such as target inhibition. 
We address in this paper the challenge of identifying features of antibodies that may influence antibody function. We design 
a pipeline for analyzing antibody sequences and extracting features (e.g., germline, positional motifs, etc.) and feature values 
 (e.g., the specific sequence of residues in the CDR-H3 region) that are overrepresented in one dataset, referred to here as a 
targeting set,  as compared to a reference dataset.  Our approach is data-driven, enabled by the increasing availability of amino 
acid sequences of functional antibodies in databases (e.g. Protein Data Bank (PDB) (16), IMGT (17)) and in patents. The 
pipeline is termed Antibody Sequence Analysis Pipeline using Statistical testing and Machine Learning (ASAP-SML). The 
pipeline extracts features associated with each antibody sequence, as well as features specific to the CDR-H3 region due to its 
role as the primary specificity determinant of most antibodies (18, 19). ASAP-SML then utilizes several machine learning 
techniques and statistical testing to determine important and statistically significant features that distinguish the sequences of 
targeting antibodies from the sequences within the reference antibodies and, if appropriate, to recommend combinations of 
design features that can be utilized during efforts to improve the binding properties of existing antibodies or to search for new 
antibodies that target an antigen of interest. 
The pipeline can be applied to contrast any two antibody data sets. For example, the targeting set may contain antibodies 
that interfere with their biological targets, collected through experiments, patents and/or database searches, while the reference 
set may contain antibody sequences that are curated from the Protein Data Bank and other reference sources. In this context, 
and for large and diverse target and reference sets, ASAP-SML operates to identify features that are overrepresented or 
underrepresented within the target set in comparison to the reference set. To demonstrate the use of ASAP-SML, we apply it 
to analyze eight datasets of antibodies that inhibit matrix metalloproteinases (MMPs). The MMPs are a family of zinc-
dependent enzymes that play numerous roles in normal physiology and development, but under pathological conditions, 
dysregulated MMPs can facilitate cancer progression (20, 21), undesired inflammation (22), and other conditions. Among 
hundreds of features, ASAP-SML identified several salient feature values for the MMP-targeting antibody data sets that 
distinguish it from reference data sets. We note that analysis via our pipeline may be confounded by limited data availability, 
or differences in antibody sequences that arise for reasons outside of function disruption (e.g., the specific antibody libraries, 
or screening procedures used to isolate antibodies of interest).  
 
Methods 
ASAP-SML overview 
The ASAP-SML pipeline comprises five steps (Figure 1). In the Data Preparation step, amino acid sequences for both targeting 
antibodies and reference sequences are prepared for use within the pipeline. In the Sequence Numbering step, each antibody 
sequence is annotated with a numbering scheme to allow for the identification of the six Complementary Determining Regions 
 (CDRs), three on the heavy chain (H1-H3) and three on the light chain (L1-L3)) directly involved in antigen binding (23), and 
the remaining Framework Regions (FR). In the Feature Extraction step, features associated with each antibody sequence 
(predicted germline and canonical structures of CDRs) and features specific to the CDR-H3 region (Isoelectric point (pI) and 
frequent positional motifs) are extracted. In the Analysis step, salient features are identified using statistical testing and machine 
learning techniques. Finally, in the Design Recommendation step, decision trees (24) are used to identify combinations of 
salient feature values for inclusion in targeting antibody sequence design. The ASAP-SML pipeline was released as an open-
source python code. The pipeline and all datasets are available on GitHub (https://github.com/HassounLab/ASAP-SML). 
Data, and data preparation 
The user inputs two data sets, a targeting set and a reference set. The user may partition sequences within each set into groupings, 
each referred to as a dataset. Such datasets, for example, may be collected through different experiments or data sources. 
ASAP-SML accommodates various size sets and datasets. The numbering and feature extraction steps of our pipeline analyze 
every sequence within each set. In the analysis and design recommendation steps, sequences are sampled, and analysis results 
are aggregated across a large number of sampling iterations, k. We assume a default iteration number k = 100. To facilitate 
Figure 1. ASAP-SML pipeline overview. Antibody sequences in the targeting and reference sets are inputted into the 
pipeline to perform sequence numbering, feature extraction, sequence and feature analysis, and design recommendations. 
 sampling, the median size among the datasets within the targeting set is selected as a desired dataset size. Each dataset is then 
either sampled or duplicated to achieve the desired dataset size. When sampling is required, the number of sampled sequences 
in the targeting set is set to the product of the desired dataset size times the number of datasets. This size is also used for the 
number of desired sampled sequences in the reference set and drives the numbers of samples per dataset in the reference set. 
The sampling parameters for the targeting and reference datasets can be overridden by the user.  
Antibody sequence numbering 
Aligning antibody sequences to a consensus sequence through a numbering scheme enables dividing an antibody sequence into 
six Complementary Determining Regions (CDRs), which are directly involved in antigen binding, and Framework Regions 
(FRs). We elected to use the Chothia numbering scheme (25) rather than other common numbering schemes, e.g., IMGT (26), 
Kabat (27), Martin (3), and AHo (28). This decision facilitated further downstream analysis when predicting CDR-H3 canonical 
structures using PIGS, which depends on the Chothia numbering scheme. ANARCI (6) is used to assign the Chothia numbering 
scheme to each antibody sequence in the targeting and reference sets.  
Feature extraction 
We extract four types of features in this step, germline, CDR canonical structure, pI (isoelectric point) range, and frequent 
positional motifs in CDR-H3. For each sequence, values for each feature are determined and recorded in a vector we refer to 
as a feature fingerprint. Each entry in the fingerprint is assigned either a "1" or "0," indicating the presence or absence of a 
particular feature value within the antibody sequence. The number of possible feature values, and therefore the width of the 
fingerprint, is dependent on the sequences in the reference and targeting sets. 
Germlines are encoded in immature B cells and are used as templates for generating diversity during selection of antibodies 
against specific targets (25). Putative germlines for each heavy and light antibody sequences on the V and J regions (HV, HJ, 
LV, and LJ) are assigned using ANARCI. ANARCI performs an alignment between the query antibody sequence and multiple 
pre-built Hidden Markov Models (HMMs). The putative germline is determined for an antibody sequence by the most 
significant alignment among all HMMs for a domain type of a particular species (Human, Mouse, Rat, Rabbit, Pig or Rhesus 
Monkey). ASAP-SML allows germline assignments from any of the species included in ANARCI. As some allelic variations 
involve a single base change, they were ignored for all germline assignments.  
Structural conformations for the highly variable CDRs are known as canonical structures. These structures can be predicted 
based on both loop length and amino acid identities at specific position (25). Here, we use the canonical structure determination 
rules introduced in the Prediction of ImmunoGlobulin Structure (PIGS) database (10) to determine if a CDR canonical structure 
 assignment can be made for a given sequence, and, if so, the specific canonical structure is assigned. 
Due to the important role of the CDR-H3 region in antibody-antigen interaction specificity, two types of features, pI and 
frequent positional motifs, are generated to characterize antibody sequences. The isoelectric point (pI) is defined as the pH 
value when net positive and negative charges of an amino acid sequence are balanced. pI values impact protein properties 
including solubility and stability (29). pI values of CDR-H3 sequences are calculated using bio.sequtils.isoelectricpoint from 
the biopython package (30). PI values are binned with a data-driven method. The range [0, 14] is initially divided into two 
equal sized bins, and then recursively halved. Bin halving is terminated if a bin contains less than 10% of antibody sequences 
or if the bin size reaches a range of pI values equal to or less than 0.3. This range is assumed as the minimum range that provides 
specificity differentiation. 
We define motifs as sequential amino acid sequences ranging from 2 to 10 amino acids in length within the CDR-H3 region. 
We consider motifs along with their positional information. The starting point of a positional motif is defined using the position 
of the first amino acid within the motif. Each positional motif is labeled with its starting point, an underscore, and the amino 
acid sequence. For example, positional motif "4_AL" indicates that there is a motif of length two consisting of sequence "AL" 
that starts at position four of the CDR-H3 region. For each antibody sequence in the targeting and reference subsets, the two 
most frequent positional motifs of each length in the CDR-H3 region are included in the feature fingerprint, thus allowing for 
a variety of subsequence lengths for the positional motifs. 
Sequence and feature analysis 
Several analysis methods are used to contrast the sequence and feature fingerprints for the targeting and non-targeting sets. 
First, pairwise similarity is computed based on both sequence similarity and also on fingerprint similarity for each pair of 
sequences. Pairwise similarity of the heavy chain and light chain sequences is calculated for the Chothia-numbered sequences. 
When comparing two sequences, the similarity of amino acids in each position is looked up in the BLOSUM62 matrix, which 
provides a match/mismatch score between two amino acids in reference to protein sequences in the BLOCKS database (31). 
An amino-acid insertion between two numbered positions or a deletion at a numbered position is considered as a gap at the 
position in question. Default gap penalties are applied. The match/mismatch scores are summed and rescaled based on min-
max normalization (32). The feature rescaling step computes a score that is first adjusted by the minimum set score over the 
set of match/mismatch scores for each chain, and then normalized by dividing the adjusted score by the difference between the 
minimum and maximum set scores.  The rescaling step thus eliminates contributions to the similarity scores due to constant 
region sequences within the light chains and within the heavy chains. The rescaled normalized score is used as the pairwise 
 sequence similarity score.  
When comparing feature fingerprints, pairwise similarity is computed per fingerprint segment corresponding to each feature 
(pI and frequent positional motifs) or feature region (germline-HV, germline-HJ, germline-LV, germline-LJ, CDR-H1, CDR-
H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3). For each segment, the similarity score is computed using the Jaccard index, 
which computes the size of the common features divided by the number of features present in either feature fingerprint. Each 
segment score is given a weight of 1. The weighted sum of the segment scores, normalized to the maximum possible score, 
provides the pairwise fingerprint similarity score. 
Pairwise similarity scores are visually inspected using heat maps. Statistical testing is then used to quantify sequence and 
feature similarity trends. Our first statistical test examines the within-set similarity in the targeting set against the within-set 
similarity for the non-targeting set. Our null hypothesis assumes that the pairwise similarity scores in the targeting set have the 
same statistical distribution as those in the reference set. Our second test examines how the extracted features correlate with 
the heavy-chain antibody sequences and with the light- chain antibody sequences. Our null hypothesis assumes that there are 
no differences in how the extracted features correlated with the heavy and light chain sequences. A one-tailed Wilcoxon rank-
sum test from the scipy.stats.mannwhitneyu python package is used to perform these statistical tests. The test is repeated for k 
iterations, where representative datasets are created each time through either sampling or duplication. The test is significant if 
all iterations report a p-value less than 0.05. 
The second analysis method identifies salient feature values that differentiate the targeting and reference sets. Statistical 
testing for each feature value for the features in Table 1 using Fisher Exact Test (FET) identifies statistically significant feature 
values with p-values less than 0.05. Additionally, feature selection is performed using a random forest algorithm 
(sklearn.ensemble python package), and importance scores are calculated. FET analysis and random forest analysis are repeated 
for k iterations. The reported p-value and rank for each feature are averaged across k iterations. Unlike FET, a frequentist 
approach, feature selection evaluates the contribution of feature values to classification. Therefore, the two tests provide 
complementary analysis. 
While salient feature analysis identifies feature values that differ between sets, a third analysis method evaluates the 
contributions of features or combination of features in classifying MMP-targeting and non-targeting sequences. We evaluate 
the contributions using all features or using only one type of feature. To ensure that the results are consistent regardless of the 
classification method, three classification techniques are used: Support Vector Machine (SVM) (33), random forest (34) and 
Adaptive Boosting (AdaBoost) algorithms (35). The classification accuracy is measured using AUC, the area under the 
 Receiver Operating Characteristic (ROC) curve, based on ten-fold cross-validation. Therefore, the set of sequences is randomly 
partitioned into 10 equal-size subsamples. Of the 10 subsamples, a single subsample is used for validation while the remaining 
9 subsamples are used as training data. To achieve ten-fold validation, this process is repeated 10 times, where a different 
subsample is selected each time for validation. Further, the AUC is averaged across k sampling iterations. 
Design recommendation using design recommendation trees 
The prior analysis step identifies salient features in the targeting antibody set. The design recommendation step identifies 
combinations of presence/absence of such feature values that are distinct within each set. To this end, ASAP-SML learns a 
decision tree, a flow-chart like structure that segments the data into sets that have particular features. The decision tree therefore 
identifies combinations of non-conflicting salient features that are distinct when comparing the targeting dataset with the 
reference dataset. Further, we augment the decision tree to show the percentage of existing sequences with such combination 
features in both reference and targeting set. With the exception of leaf nodes, each node in the tree tests the presence or absence 
of a particular feature value. The feature value with the lowest misclassification rate, the Gini impurity (36), is used to partition 
the node into two child nodes. Left branches represent the true outcome of the test, while the right branch represents the false 
outcome. Decision tree branching is stopped when at least one leaf has less than 5% of the total number of antibody sequences 
Table 1. Extracted features. Listing of (a) features in the fingerprint vector, (b) regions within antibody that exhibit the 
feature, (c) software extraction method, and (d) number of possible feature values for the MMP-targeting set test case. 
Feature 
 
(a) 
Region 
 
(b) 
Extraction 
method 
(c) 
Number of possible  
feature values for  
MMP-targeting set 
(d) 
Germline 
HV 
ANARCI 
110 
HJ 6 
LV 99 
LJ 11 
CDR Canonical Structure 
H1 
PIGS 
5 
H2 5 
H3 4 
L1 4 
L2 1 
L3 1 
Isoelectric Point (pI) 
(CDR-H3) 
 biopython package 8 
Frequent Positional Motifs 
(CDR-H3)  ASAP-SML script 46 
 
 
 associated with the root node. 
The decision tree algorithm outputs a colored-tree diagram (Figure S3). Each node in the decision tree is colored based on 
the ratio of its number of sequences from each targeting and reference sets. Nodes with more targeting antibody sequences are 
colored in blue, and nodes with more reference antibody sequences are colored in orange. A path from the root node to a 
particular tree node represents a combination of feature values that are either mostly excluded or included for the sequences 
associated with the tree node.  The true branches along such a path thus correspond to feature values that are present in the leaf-
node sequences, while false branches correspond to excluded feature values. The sklearn.tree.DecisionTreeClassifier (37) 
python package is used to construct the decision tree. 
While the decision tree identifies a model that best classifies the sequences, our intention is to utilize the decision tree to 
identify combinations of feature values to use when designing targeting sequences. We therefore augmented the tree with two 
new metrics, split efficiency (SE) and error rate (ER). Split efficiency is calculated as the number of targeting antibody 
sequences in the current node divided by the number of targeting antibody sequences in the root node. Split efficiency reflects 
the portion of sequences in targeting set that has the combination of valid feature value following the path from root to current 
node. The split efficiency of a node is less than or equal to that of its parent node. Error rate is calculated as the number of 
reference antibody sequences in the current node divided by the number of antibody sequences from both the targeting and 
reference sets in the current node. Error rate tells the likelihood of having a non-targeting sequence when including the design 
features from the root to the current node. Error rates are independent of tree depth (distance from root). To identify the best 
combination of design features, all paths from root to nodes that are dominated by the targeting sequences are analyzed with 
the goal of identifying node(s) that maximizes split efficiency and minimizes error rate. We refer to this newly labeled decision 
tree as a design recommendation tree. 
Results 
MMP-targeting and reference data 
The data used to illustrate the functionality of ASAP-SML is composed of publicly available amino acid sequences of 
antibodies reported to inhibit MMPs and two reference datasets. A summary of the MMP-targeting antibody datasets is listed 
in Table 2, ordered in decreasing number of antibody sequences available in each dataset. Seven of the eight datasets were 
collected from patents in which experimental data is presented confirming the inhibitory activity of at least a portion of the 
antibody sequences that bind to a member of the human MMP family. We note that MMP-targeting datasets 1-5 all originated 
 from work conducted at a single company (Dyax) and these datasets contain sequences almost exclusively based on the IGHV3-
23 germline (38). An additional dataset, labeled MMP-targeting 8, was collected from the PDB by searching for MMP-targeting 
antibodies using the keywords "MMP" and "antibody". The identified antibody sequences were deposited by Udi et al (39). 
The sizes of the MMP targeting datasets are highly variable. The largest dataset, MMP-targeting set 1, has 621 antibody 
sequences, while MMP-targeting datasets 7 and 8 only have 4 antibody sequences each. Antibody sequences collected here 
target MMP-2, -9, -12, -13, -14, -26. MMP-targeting datasets 2 and 5 are culled from the same patent (40), where sequences in 
dataset 5 inhibit MMPs, while sequences in dataset 2 are known to only bind to MMPs.  
Upon initial analysis, there were 24 antibody sequences in the MMP-targeting set that were assigned by ANARCI to non-
human or to non-murine germlines. These sequences were removed from the MMP-targeting set. Additionally, high sequence 
similarity was observed within some of the individual datasets due to the presence of antibody sequences from in vitro affinity 
maturation campaigns in which point mutants of a single parent antibody were evaluated for improved affinity.  BLAST-
CLUST (46) was used to cluster highly similar sequences (up to 95% similarity in residues after sequence alignment), and to 
select a representative sequence for each cluster. Clustering revealed that the largest dataset, MMP-targeting dataset 1, contains 
only 16 distinct clusters from the 621 antibody sequences extracted from the US8013125B2 patent. MMP-targeting dataset 
MMP-targeting 
Dataset 
Number 
Targeted MMPs Sequences source Reference 
Number of 
sequences 
Number of 
representative 
sequences 
1 MMP-2, MMP-9 US8013125B2 (41) 621 16 
2 MMP-12 US8114968 (40) 69 64 
3 MMP-26 US20060036076A1 (42) 44 43 
4 MMP-14 US7745587B2 (43) 12 12 
5 MMP-12 US8114968 (40) 12 12 
6 MMP-13 WO2007065037A2 (44) 11 11 
7 MMP-9 US8377443 (45) 4 1 
8 MMP-14 Protein Data Bank (39) 4 1 
Total Number of 
sequences    777 160 
Table 2. The MMP-targeting antibody set comprises 8 datasets.  
 
 
 2, which includes 69 antibody sequences extracted from patent US8114968, still contained 64 distinct sequences after clustering, 
MMP-targeting dataset 3 contains 43 distinct sequences after clustering. A total of 160 representative sequences were merged 
into a combined MMP-targeting set for further analysis. This representative set is referred to at the MMP-targeting set.  
To identify a set of antibody sequences that do not bind to or inhibit MMPs, the PDB was queried on May 24, 2017 for 
human and murine sequences that do not bind to or inhibit MMPs. The inclusion of both human and murine sequences in this 
reference set was deliberate, as some of the MMP-targeting antibodies present in the datasets are murine in origin due to the 
immunization-based strategies used to generate the sequences. To avoid overrepresentation of highly similar antibody 
sequences in the reference dataset, the database was queried for representative sequences with 95% or fewer identical residues. 
Only antibody sequences with paired heavy and light chains and complete variable regions were selected. Sequences that were 
assigned by ANARCI to non-human or to non-murine germlines were excluded. The resulting reference dataset consisted of 
183 human antibody sequences and 197 murine antibody sequences. This reference dataset is referred to as the PDB-reference 
set. 
When analyzing the MMP-targeting set against the PDB-reference set, we observed that 92.50% of the MMP-targeting set 
sequences were assigned to IGHV3-23, consistent with the origination of MMP-targeting sets 1-5 from Dyax (38). This feature 
is therefore not likely to be functionally significant. To remove the potentially confounding effects of this germline 
overrepresentation, we selected a subset of the MMP-targeting set that contains only the subset of sequences with the IGHV3-
23 germline and then used BLASTCLUST to select representative sequences. This reduced set is referred to as the MMP-
IGHV-targeting set. Instead of comparing this set against the PDB-reference set, which contains a large variety of germlines, 
we compared the MMP-IGHV-targeting set against IGHV3-23 human antibody heavy-chain sequences from former studies 
(European Molecular Biology Laboratory accession numbers AM076988–AM083316) (47-50). These sequences, which were 
utilized to study CDR diversity within a controlled germline context, are not known to bind to any specific targets. This 
reference set is referred to as the IGHV-reference set. As only the heavy chain sequences were available for the IGHV-reference 
set, ASAP-SML was applied to compare the MMP-IGHV-targeting and the IGHV-reference sets. MMP-IGHV-targeting set 
has 134 representative sequences and the IGHV-reference dataset has 4673 representative sequences.  
We applied ASAP-SML to these sets. For each set, sequences were numbered and then extracted. The analysis is reported 
below first for the MMP-targeting against the PDB-reference set, followed by the MMP-IGHV-targeting against the IGHV-
reference set. The design recommendation step is only demonstrated for the MMP-targeting against PDB-reference set. The 
MMP set described in Table 1, its features, and the mapping from the original set to the MMP-targeting set and the MMP-
 IGHV-targeting set, are provided in Table S1. Sequence details and analysis of the MMP-targeting set against the PDB-
reference sets are provided in Table S2.  Sequence details and analysis of the MMP-IGHV-targeting set against the IGHV-
reference set are provided in Table S3. 
Similarity analysis for MMP-Targeting vs PDB-reference sets  
Heat maps.  To analyze similarities within and between MMP-targeting vs PDB-reference sets, heat maps were constructed 
 
 
Figure 2. Heat maps comparing the reference set, consisting of human and murine antibody datasets, with the MMP-
targeting set, consisting of datasets 1-8. (a) Heavy-chain sequence similarity heat map, (b) Light-chain sequence similarity heat 
map, (c) Extracted-feature similarity heat map. To visualize within-set similarity for the reference set and within-set similarity for 
the MMP-targeting set, the sets are marked with Block 1 and Block 2, respectively, on the extracted-feature heat map. 
 
 using heavy-chain pairwise sequence similarity (Figure 2a), light-chain pairwise sequence similarity (Figure 2b), and feature 
value pairwise similarity (Figure 2c). For all heat maps, datasets within the MMP-targeting set exhibit high pairwise similarity, 
despite the fact that the datasets include sequences that target a variety of MMPs (e.g., MMP-2, MMP-9, etc.). This trend 
appears stronger in the heat map for feature values (Figure 2c), but less so in the heat map for the light-chain sequences (Figure 
2b). Further, heavy-chain pairwise similarity tracks the extracted-feature similarity more so than the light-chain pairwise 
similarity.   
Statistical testing. ASAP-SML provided a statistical test to confirm that within-set similarity in the MMP-targeting set is 
higher than within-set similarity for the reference set. The testing was performed for the targeting pairwise similarity data for 
heavy-chain sequences, light-chain sequences, and extracted features, against their respective pairwise similarity data of the 
reference set, ASAP-SML performed a one-tailed Wilcoxon rank-sum test to evaluate the similarities within sets. The test was 
repeated k = 100 times. The average p-values for each of the three heat maps was less than 0.001, indicating statistical 
significance. Therefore, pairwise within-set similarity scores for the MMP-targeting set are higher than those for the reference 
set, confirming the observation that the relationships among the set of antibody sequences in the MMP-targeting set are closer 
than those sequences found in the reference set.  
      ASAP-SML also provided a statistical test to confirm that the extracted features better correlate with the heavy chain 
antibody sequences than with the light chain antibody sequences, as indicated by visual inspection of the heat maps. Differences 
between heavy-chain pairwise sequence similarity and feature-value pairwise similarity, as computed for Figures 2a and 2c, 
and differences between light-chain pairwise sequence similarity and feature-value pairwise similarity, as computed for Figures 
2b and 2c were computed. Our null hypothesis assumes that these two computed differences have the same statistical 
distribution. A one-sided Wilcoxon rank-sum test was then performed on the differences to evaluate the alternate hypothesis 
that the computed differences between heavy-chain pairwise sequence similarity and feature-value pairwise similarity is more 
significant than the computed differences between light-chain pairwise sequence similarity and feature-value pairwise 
similarity. The test was performed for k=100 repetitions. The p-value was less than 0.001 for each repetition. Therefore, the 
extracted-feature heat map (Figure 2c) is more correlated with the heavy-chain heat map (Figure 2a) than with light-chain heat 
map (Figure 2b). With the limited sequence diversity present within the targeting set, the observed correlations may be 
artifactual in nature. Larger and more diverse collections of targeting sets would be needed to fully validate the correlations 
observed in our analyses. 
 Salient feature-value identification for MMP-Targeting vs PDB-reference sets 
ASAP-SML sought to identify individual extracted feature values associated with the MMP-targeting set (Table S2f). For the 
300 extracted features, the FET identified 35 significant features, while the random forest model for feature selection identified 
60 features as important.  Of these feature values, 26 were identified by both methods. Out of these 26 features, 8 germlines, 5 
CDR canonical structures, 2 pI ranges and 11 frequent positional motifs were identified. The FET identified 18 of the 184 
possible heavy chain features as significant, while only 7 of 116 possible light chain features were identified as such.  
To analyze frequencies of salient feature values, frequency analysis is applied to the MMP-targeting and PDB-reference 
sets (Table S2e). The frequency of the most “important” distinguishing feature based on both FET and importance analysis, 
germline IGHV3-23, is 92.50% in the MMP-targeting sequences but only 5.26% in the reference dataset sequences. This is 
likely the result of the datasets used as inputs for the pipeline in this work and may not be directly attributable to functional 
Table 3. Top 5 salient feature values as determined by Fisher Exact Test. 
Rank Feature Feature value Average p-value 
Frequency in 
PDB-reference set 
Frequency in 
MMP-targeting set 
1 Germline HV IGHV3-23 4.51E-60 5.26% 92.50% 
2 CDR Canonical Structure H2 Type 6 4.02E-34 27.11% 94.38% 
3 Germline LJ IGKJ3 2.64E-05 2.11% 16.25% 
4 Germline HJ IGHJ6 1.64E-04 16.05% 36.25% 
5 Germline LV IGKV1-39 1.74E-04 3.95% 17.50% 
 
Table 4. Top 5 salient feature values as determined by feature selection. 
Rank Feature Feature value Importance score 
Frequency in 
PDB-reference set 
Frequency in 
MMP-targeting set 
1 Germline HV IGHV3-23 0.2605 5.26% 92.50% 
2 CDR Canonical Structure H2 Type 6 
0.1084 27.11% 94.38% 
3 
CDR Canonical 
Structure H2 
 
Type 5 0.0699 39.47% 0.00% 
4 Germline HJ IGHJ2 0.0266 1.25% 18.95% 
5 Germline LJ IGKJ3 0.0150 2.11% 16.25% 
 
 differences. The frequency of the second most important feature, CDR-H2 canonical structure type 6, is 94.38% in the MMP-
targeting sequences and 27.11% in the reference sequences. The differences in frequency of the remaining top 5 features (Tables 
3 and 4) were less than ~40%. The absolute differences in the frequency of feature values in the reference and MMP-targeting 
set are reported (Table S2e). A feature value with high differences in frequency (> 50%) is considered a biasing feature, a 
feature that can distinguish two sets with high classification accuracy. Germline IGHV3-23 and CDR-H2 canonical structure 
type 6 are the two biasing features when analyzing the MMP-targeting versus PDB-reference sets. We emphasize that these 
features are biasing within the context of our datasets. However, these features may not be biasing when considering a different 
MMP-targeting dataset and/or different reference sets. 
To explore if any of the salient features are correlated, associations amongst pairs of features from the MMP-targeting and 
the PDB-reference sets were computed (Table S2g).  The Jaccard coefficient is used to compute the co-occurrence of each pair 
of binary (0 or 1 depending on feature presence or absence) features (51). Given two feature vectors for sequences within a 
particular dataset, the Jaccard coefficient represents the proportion of sequences that have both features present relative to the 
total number of sequences where at least one of the two features are present. A high Jaccard coefficient score (> 0.8) suggests 
strong association relationship between two feature values. Within the MMP-targeting set, the two biasing features identified 
in previous frequency analysis, germline IGHV3-23 and CDR-H2 canonical structure type 6, have strong association with a 
Jaccard coefficient score of 0.90. Additionally, CDR-H1 canonical structure type 1, CDR-L2 canonical structure type 0 and 
CDR-L3 canonical structure type 0 have strong association with each of the two biasing features. There were also highly 
associated features within the PDB-reference set (Table S2g). All of these observations confirm that our pipeline is able to 
identify features that are distinct between two datasets. 
Contribution of features to classification for MMP-Targeting vs PDB-reference sets 
To assess if extracted features can distinguish targeting and reference sequences, ASAP-SML analyzed the performance of 
three classification algorithms, SVM, random forest, and AdaBoost, in separating MMP-targeting from reference antibody 
sequences using all features or based on one type of feature only. To assess the impact of the biasing features, classification 
was re-run with the exclusion of biasing features and their associated features. In both cases, AUC data using all three 
algorithms yielded similar ROCs. The following discussion explicitly refers to the results based on the SVM AUC data, but it 
is generalizable to other algorithms.   
Classification using all features with SVM yielded an AUC of 0.9812 (Figure S1a). Classification was re-run while retaining 
one feature-at-a-time (Figure S1b-e) yielding the following AUC values: germline, AUC=0.9750; CDR canonical structures, 
 AUC=0.8414; pI, AUC=0.6383, and frequent positional motifs, AUC=0.6960. Due to the biasing features, the AUC was high 
when using germline and CDR canonical structure features.  
We further investigated classification when including subsets of features (Figure 3).  The biasing features are germline 
IGHV3-23 and CDR-H2 canonical structure type 6, while CDR-H1 canonical structure type 1, CDR-L2 canonical structure 
type 0 and CDR-L3 canonical structure type 0 are deemed associated features. Excluding biasing features and their associated 
features and using the remaining features that are included in Table S2e, SVM classification yielded an AUC of 0.8668 (Figure 
3a). Classification while retaining one feature-at-a-time (Figure 3b-e) yielded a range of AUC values: germline, AUC=0.8396; 
CDR-canonical structure, AUC=0.6248; pI, AUC=0.6383, and frequent positional motifs, AUC=0.6960. Despite excluding the 
biasing germline (IGHV3-23), the germline AUC was surprisingly high. Examining the frequencies of the non-excluded 
germlines, HJ, LV, and LJ, showed that the germlines of the two datasets were mutually exclusive (Table S2e), thus providing 
two groupings of biasing germline features. The AUC for the CDR canonical structure was significantly lower when excluding 
the biasing features due to the removal of CDR-H2 canonical structure type 6 and other associated CDR canonical structure 
features (CDR-H1, CDR-L2 and CDR-L3) as classification features. The AUC for pI and the frequent positional motifs were 
identical to those in the prior classification case. We further investigated the impact of removing all germline features and 
associated CDR canonical structure features and retaining the remaining CDR canonical structure features, pI features and 
frequent positional motifs features. Classification yielded an AUC of 0.7599 (Figure 3f). The group of features utilized in 
Figure 3f proved an important orthogonal predictor for classification. Further, many such features were identified earlier as 
important using FET and importance feature selection. These findings suggest that combinations of extracted features can 
distinguish the sequences in the MMP-targeting vs PDB-reference sets. For more large and diverse datasets than what we have 
analyzed herein, this classification procedure can highlight features for further biological characterization to determine their 
exact roles in binding to targets and disrupting biological function.  
Salient feature-value identification for MMP-IGHV-targeting and IGHV-reference sets 
For the 57 extracted features, FET identified 17 significant features, while the random forest model for feature selection 
identified 19 features as important; 7 of these feature values were identified in both methods (Table S3f). Out of these 7 features, 
1 germline, 1 CDR canonical structures, 1 pI ranges, and 4 frequent positional motifs were identified. Frequency analysis of 
features within the MMP-IGHV-targeting and IGHV-reference sets (Table S3e) showed that none of the salient features 
identified in FET or feature selection have high frequency (> 80%) or high difference in frequency between the two sets (>50%). 
This result suggests that there are no biasing features when analyzing the MMP-IGHV-targeting and IGHV-reference sets. 
  
Figure 3. Area Under ROC Curves (AUC) for classification using SVM, random forest AdaBoost algorithms, while 
excluding biasing features and their associated features. (a) AUC based on all included features, (b) AUC based on 
germline features, (c) AUC based on CDR canonical structure features, (d) AUC based on pI features, (e) AUC based on 
frequent positional motifs features, (f) AUC based on all features excluding all germline features and associated CDR 
canonical structure features.  
 
 Some identified important features, such as Germline IGHJ4, had small percentages of differences of frequency between the 
MMP-IGHV-targeting and the IGHV-reference set when performing feature selection. It was possible to identify that such 
features as important because feature selection identifies combinations of important features and not independent important 
features. 
Contribution of features to classification for MMP-IGHV-targeting vs IGHV-reference sets 
Since no biasing features are identified in the MMP-IGHV-targeting and IGHV-reference sets, the full set of extracted features 
are used in classification (Figure S2). SVM yielded an AUC of 0.6941 (Figure S2a). Classification while retaining one feature-
at-a-time (Figure S2b-e) yielded a range of AUC values: germline, AUC=0.5658; CDR-canonical structure, AUC=0.6023; pI, 
AUC=0.5648, and frequent positional motifs, AUC=0.6434. The AUCs when retaining one feature-at-a-time were lower than 
the AUCs when using all features. The classification yielded AUCs for CDR-canonical structure and frequent positional motifs 
that are higher than AUCs for germline and pI. These findings suggest that combinations of extracted features can better 
distinguish MMP-IGHV-targeting vs IGHV-reference set antibody sequences than a single type of feature.  
Comparing analyses on MMP-targeting vs PDB-reference sets and MMP-IGHV-targeting vs 
IGHV-reference sets 
The first case study, MMP-targeting vs PDB-reference sets, aimed to compare the MMP-targeting set against a diverse set of 
non-targeting sequences culled from the PDB.  Frequency analysis identified biasing features and their associated features, 
which were removed for subsequent ASAP-SML analysis. To provide a more impartial analysis, we sought a second case study, 
where the reference set consisted of sequences with the HV germline that was predominant in the MMP-target set. Salient 
features identified for the two data sets were compared (Table S4a). When using FET, there were 7 common features out of 28 
significant heavy-chain features identified in MMP-targeting vs PDB-reference analysis, and out of 17 significant heavy-chain 
features identified in MMP-IGHV-targeting vs IGHV-reference analysis. When using importance analysis, there were 12 
common features out of the 36 important heavy chain features identified in MMP-targeting vs PDB-reference analysis and out 
of 19 important heavy chain features identified in MMP-IGHV-targeting vs IGHV-reference analysis. Four features were 
identified in common across FET and importance analysis (CDR-H3 canonical structure type 2, pI range 0.0-3.5, and motifs 
2_YG and 5_YY), indicating that these features are consistently distinct when comparing the MMP sets against either of the 
two reference sets. However, this analysis alone cannot directly determine whether these features possess biological 
significance.  
AUC plots (Figure 3 vs Figure S2) for the two case studies are compared. Overall, AUCs in the MMP-IGHV-targeting vs 
 IGHV-reference sets were lower than those in the MMP-targeting vs PDB-reference sets. In the germline case, mutually 
exclusive features contributed heavily to the classification of the MMP-targeting vs PDB-reference sets, while there were no 
such mutually exclusive features in the MMP-IGHV-targeting vs IGHV-reference sets. When classifying using only CDR 
canonical structures, classification accuracy was lower for the MMP-IGHV-targeting vs IGHV-reference sets than for the  
MMP-targeting vs PDB-reference sets. The latter analysis used features associated with both the heavy and light chains, while 
the former analysis used only the heavy-chain features. Classification using pI features yielded similar AUC results. The low 
frequency of positional motifs within MMP-IGHV-targeting and IGHV-reference sets contributed to low AUC result. 
Importantly, for both analyses, using combinations of features was more effective in classification than using any one single 
feature. Determining how these combinations affect biological function requires a more diverse and detailed experimental 
dataset than the one utilized in this study.  
Design recommendations using decision trees for the MMP-targeting vs PDB-reference sets 
To explore how the output of the ASAP-SML analysis could guide antibody design, a design recommendation tree (Figure 4) 
was constructed for the comparative data based on the corresponding decision tree (Figure S3). Each path from root to a blue 
node highlights combinations of feature values, which are either present or absent, that are more likely to be associated with 
the targeting antibody sequences based on the statistical analyses described above. Each combination provides a 
recommendation for feature values to include (those along true branches) and to exclude (those along false branches). Since 
some combinations of these features appear in MMP-targeting antibodies, decision trees may have value in designing 
collections of additional sequences in search of further function-disrupting sequences. Split efficiency, error rate, and the root-
to-node path length are considered when identifying the best design recommendation or when analyzing design tradeoffs. As 
expected from identifying the IGHV3-23 germline as a biasing feature, utilizing the presence of feature-value SC1 
(IGHV3-23 germline for HV) results in identifying 92.50% of MMP-targeting sequences, with a 5.67% error rate. 
Utilizing the presence of SC1 and absence of SC2 (IGLJ3 germline for LJ) results in identifying 78.75% of sequences with 
4.04% error rate. The lowest error rate for the targeting set is the result of a combination consisting of the presence of SC1 
(IGHV3-23 germline for HV), absence of SC2 (IGLJ3 germline for LJ), absence of SC5 (IGKJ1 germline for LJ), and absence 
of SC8 (IGLJ1 germline for LI) and absence of SC10 (PI 3.9375-4.375) resulting in a node with a 0% error rate for 49.38% of 
the MMP-targeting set. Design variations based on decision recommendation (including SC1 while avoiding other conditions) 
may lead to additional testing candidates. We note however that these recommendations are specifically based on our datasets 
and are only provided to depict the decision tree functionality of ASAP-SML.  
  
  
Figure 4. Design recommendation tree for the MMP-targeting antibody test case. Each node lists the number of MMP 
sequences (X), and the number of reference sequences (Y), along with the splitting efficiency and error rate. The label under 
each node, when present, reflects the splitting feature value and is expanded in the legend. 
 
 
 Discussion 
This paper describes the implementation of ASAP-SML, a pipeline for identifying features common in one set of antibodies in 
reference to another set. This pipeline extracts residue-based and CDR-H3 region features from primary amino acid sequences 
and supports several analyses to identify features and feature values that are significantly overrepresented in a targeting 
antibody set when compared to a reference set. Further, ASAP-SML builds a design recommendation tree to aid in identifying 
and evaluating combinations of feature values for inclusion or exclusion when designing further candidate targeting antibody 
sequences. We are not aware of any other analysis pipelines that analyze antibody sequences in the ways described within. As 
with all data-driven approaches, however, the value of the analyses and generalizability of the findings depend heavily on the 
availability of sufficient quantities of high-quality data. 
In analyzing sets of MMP-targeting antibody sequences against PDB-reference sequences, we found that features associated 
with the antibody heavy chain are much more likely to differentiate our MMP-targeting sequences from the selected PDB- 
reference antibody sequences. This result is consistent with experimental findings that show that antibody heavy chains play 
dominant roles in antigen recognition (19, 42). Comparing the MMP-IGHV-targeting set against the IGHV-reference antibody 
set, ASAP-SML identified several salient features that were in agreement with those identified when analyzing the MMP-
targeting vs PDB-reference sets. While we utilized sequence clustering to minimize redundancy and identified correlation 
between variables, we note that biases in the available datasets may explain these specific observations. The use of the pipeline 
enabled identification of some frequently occurring dipeptide motifs; however, the presence of such motifs does not necessarily 
imply any functional consequence. Importantly, the analysis shows that the ASAP-SML pipeline is capable of identifying 
salient features between targeting and reference sequence sets. 
We developed design recommendation trees to identify combinations of feature values that can be used to generate additional 
sequences with features that distinguish between targeting and reference datasets. We expect that identified features and 
combinations thereof will be useful for the purpose of augmenting existing antibody libraries by identifying related sequences 
that have a higher probability of yielding antibodies that inhibit their targets, or for enhancing the affinities of existing targeting 
antibodies through affinity maturation. Further, for a sufficiently diverse targeting data set, identified features can be 
incorporated into various antibody computational synthesis approaches including de novo design or the redesign of existing 
antibodies (52). Expanding the ASAP-SML pipeline to include properties of targeted epitopes (if known), antibody subtypes, 
and/or more properties that can be determined via computational antibody prediction (6, 53) and utilizing this approach in 
combination with experimental data will enable further refinements to the pipeline.  
 While we evaluated the utility of ASAP-SML for an MMP-targeting set, we expect that ASAP-SML will be utilized as a 
general analysis pipeline for the identification of antibody features that alter the biological functions of their targets, conditional 
on the availability of datasets that support such analyses. This includes both antibodies targeting enzymes from other protein 
families and antibodies that disrupt additional biological processes such as viral entry. The ASAP-SML approach should be 
compatible with any antibody discovery effort as long as a diverse and representative set of sequencing data is available for 
both targeting and reference sets.  
Supporting information 
Figure S1. Contribution of features to classification for MMP-targeting vs PDB-reference set. AUC 
for classification using SVM, random forest AdaBoost algorithms when (a) using all features, (b) retaining germline features, 
(c) retaining CDR canonical structure features, (d) retaining pI features, and (e) retaining frequent positional motif features, (f) 
excluding germline features.  
Figure S2. Contribution of features to classification for MMP-IGHV-targeting vs IGHV-reference 
set. AUC data is reported for classification when (a) using all features, (b) retaining germline features, (c) retaining CDR 
canonical structure features, (d) retaining pI features, and (e) retaining frequent positional motif features. 
Figure S3. Decision tree output during design recommendation step when analyzing the MMP-
targeting set vs PDB-reference set. With a desired dataset size of 160, which is the size of representative MMP-
targeting sequences, and k=100 sampling iterations, each set had 160*100 sequences. The label within each node reflects the 
following: the feature value, the Gini impurity score, the number of samples within the tree rooted at that node, a value providing 
a listing of the number of samples that are from the reference set followed by the number of samples that are from the MMP-
targeting set, and a node classification label indicating if the node is dominated by reference or MMP-targeting sequences.  
Table S1. Detailed data for the collected MMP-targeting antibody sequences. (a) original sequences, (b) 
extracted features, (c) representative MMP-targeting set sequence IDs after BLASTCLUST and corresponding sequences in 
the original set, (d) representative MMP-IGHV-targeting set heavy chain sequence IDs after BLASTCLUST and corresponding 
sequences in the original set. 
Table S2. Detailed data for representative sequences in MMP-targeting vs PDB-reference sets. (a) 
sequences for MMP-targeting set, (b) extracted features for MMP-targeting set, (c) sequences for PDB-reference set, (d) 
 extracted features for PDB-reference set, (e) distribution of features, (f) statistical testing and feature selection scores for 
features in MMP-targeting and PDB-reference sets, (g) Jaccard coefficient association scores for features within the MMP-
targeting set and within the PDB-reference set. 
Table S3. Detailed data for representative sequences in the MMP-IGHV-targeting and IGHV-
reference sets. (a) sequences for MMP-IGHV-targeting set, (b) extracted features for MMP-IGHV-targeting set, (c) 
sequences for IGHV-reference set, (d) extracted features for IGHV-reference set, (e) distribution of features, (f) statistical 
testing and feature selection scores in the MMP-IGHV-targeting and IGHV-reference sets, (g) Jaccard coefficient association 
scores for features within the MMP-IGHV-targeting set and within IGHV-reference set.  
Table S4. Comparison of salient features for the two comparative sets: the MMP-targeting vs PDB-
reference sets and the MMP-IGHV-targeting vs IGHV-reference sets. 
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